Install
- 31articles · 30d
- 1+ day agolatest article
- Aug 16, 2026earliest in window
- 100%with images
- 246avg words
- Business & Industrial 24
- Economy, Business & Finance 21
- Medical 21
- Science & Technology 9
- Finance & Business 6
- Health & Wellness 6
- Crime & Law 2
- Science & Nature 2
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Tyra Biosciences Phase II SURF302 results support LG IR NMIBC with dabogratinib
4+ day, 3+ hour ago (230+ words) The Pharma Letter - Tyra Biosciences Phase II SURF302 results support LG IR NMIBC with dabogratinib US clinical-stage biotech Tyra Biosciences (Nasdaq: TYRA) yesterday announced initial results from SURF302, its Phase II study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle…...
Solstice Oncology launches with $225 million to advance neoadjuvant CTLA-4 antibody
4+ day, 6+ hour ago (209+ words) The Pharma Letter - Solstice Oncology launches with $225 million to advance neoadjuvant CTLA-4 antibody USA-based Solstice Oncology has launched with a $225 million Series A financing to advance porustobart, a second-generation, Fc-enhanced CTLA-4 antibody, into neoadjuvant treatment of colon cancer. The round…...
FDA withdraws Krazati's colorectal cancer indication after confirmatory trial miss
6+ day, 4+ hour ago (228+ words) The Pharma Letter - FDA withdraws Krazati's colorectal cancer indication after confirmatory trial miss Bristol Myers Squibb (NYSE: BMY), the US pharma major, has withdrawn the accelerated approval of Krazati (adagrasib) in combination with Erbitux (cetuximab) for KRAS G12C-mutated colorectal cancer…...
Zentalis Pharmaceuticals
3+ week, 2+ day ago (588+ words) The Pharma Letter A clinical-stage biopharmaceutical company focused on WEE1 inhibition in biomarker-selected ovarian cancer, with its lead asset azenosertib approaching a pivotal registration-enabling data readout in 2026. Zentalis Pharmaceuticals discovers and develops small molecule therapeutics targeting fundamental biological pathways in cancer....
Kynexis raises 97 million euros to advance med for cognitive disorders
3+ week, 5+ day ago (243+ words) The Pharma Letter - Kynexis raises 97 million euros to advance med for cognitive disorders Dutch clinical-stage biotech Kynexis today announced the closing of a 40 million euros ($46.3 million) Series A extension bringing total Series A financing to 97 million euros ($110 million). The financing…...
Dash Bio banks $30 million to automate development bottleneck
3+ week, 5+ day ago (275+ words) The Pharma Letter - Dash Bio banks $30 million to automate development bottleneck USA-based bioanalysis firm Dash Bio has raised $30 million in a series A round led by Oak HC/FT, money it will spend on a laboratory that hands much of…...